Expert Consensus. Management of patients with chronic retinal diseases in the current conditions of the COVID-19 pandemic in the world and in Ukraine
DOI:
https://doi.org/10.31288/oftalmolzh202128284Abstract
Expert Consensus. Management of patients with chronic retinal diseases in the current conditions of the COVID-19 pandemic in the world and in Ukraine
References
1.Berg K et al. (2016) Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol. Ophthalmology; 123 (1): 51-59. https://doi.org/10.1016/j.ophtha.2015.09.018
2.Dugel P et al. (2021) HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology; 128(1):89-99. https://doi.org/10.1016/j.ophtha.2020.06.028
3.El Hamichi S. et al. (2020) Impact of the COVID-19 Pandemic on Essential Vitreoretinal Care with Three Epicenters in the United States. Clinical Ophthalmology; 14: 2593-2598. https://doi.org/10.2147/OPTH.S267950
4.Fauser S. et al. (2014) Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am. J. Ophthalmol.; 158(3): 532-538. https://doi.org/10.1016/j.ajo.2014.05.025
5.Muether P.S et al. (2013) Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am. J. Ophthalmol.; 156(5): 989-993. https://doi.org/10.1016/j.ajo.2013.06.020
6.Ohji M. et al. (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv. Ther., 37(3): 1173-1187. https://doi.org/10.1007/s12325-020-01236-x
7.Papadopoulos N. et al. (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis; 15(2): 171-185. https://doi.org/10.1007/s10456-011-9249-6
8.Royal College of Ophthalmologists (2020) Guidance on restarting Medical Retina Services. Published 16 Jul 2020 (Available at: https://www.rcophth.ac.uk/wp-content/uploads/2020/07/Guidance-on-restart...).
9.Royal College of Ophthalmologists (2020) Medical Retinal Management Plan during COVID-19. Published 30 Mar 2020, Revised 22 Sep 2020 (Available at: https://www.rcophth.ac.uk/wp-content/uploads/2020/10/Medical-Retinal-Man...).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Віталій Фуголь
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
